457 related articles for article (PubMed ID: 10352342)
1. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
3. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Wick W; Furnari FB; Naumann U; Cavenee WK; Weller M
Oncogene; 1999 Jul; 18(27):3936-43. PubMed ID: 10435616
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Naumann U; Durka S; Weller M
Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
[TBL] [Abstract][Full Text] [Related]
6. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
[TBL] [Abstract][Full Text] [Related]
7. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing.
Wagenknecht B; Schulz JB; Gulbins E; Weller M
Cell Death Differ; 1998 Oct; 5(10):894-900. PubMed ID: 10203695
[TBL] [Abstract][Full Text] [Related]
8. Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions.
Streffer JR; Schuster M; Pohl U; Belka C; Dichgans J; Bamberg M; Weller M
Anticancer Res; 1999; 19(6B):5265-9. PubMed ID: 10697547
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer.
Rieger J; Ständer M; Löschmann PA; Heneka M; Dichgans J; Klockgether T; Weller M
Oncogene; 1998 Nov; 17(18):2323-32. PubMed ID: 9811463
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ
Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118
[TBL] [Abstract][Full Text] [Related]
11. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Roth W; Wagenknecht B; Dichgans J; Weller M
J Neuroimmunol; 1998 Jul; 87(1-2):121-9. PubMed ID: 9670853
[TBL] [Abstract][Full Text] [Related]
13. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.
Roth W; Wagenknecht B; Grimmel C; Dichgans J; Weller M
Br J Cancer; 1998; 77(3):404-11. PubMed ID: 9472635
[TBL] [Abstract][Full Text] [Related]
14. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release.
Hermisson M; Wagenknecht B; Wolburg H; Glaser T; Dichgans J; Weller M
Oncogene; 2000 May; 19(19):2338-45. PubMed ID: 10822385
[TBL] [Abstract][Full Text] [Related]
15. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
16. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
17. Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression.
Winter S; Roth W; Dichgans J; Weller M
Eur J Pharmacol; 1998 Jan; 341(2-3):323-8. PubMed ID: 9543255
[TBL] [Abstract][Full Text] [Related]
18. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.
Glaser T; Castro MG; Löwenstein PR; Weller M
Gene Ther; 2001 Mar; 8(6):469-76. PubMed ID: 11313826
[TBL] [Abstract][Full Text] [Related]
19. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
Steinbach JP; Supra P; Huang HJ; Cavenee WK; Weller M
Brain Pathol; 2002 Jan; 12(1):12-20. PubMed ID: 11770895
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
